Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Karolinska University Hospital
Estocolmo, SueciaPublications en collaboration avec des chercheurs de Karolinska University Hospital (91)
2024
-
Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy
Radiotherapy and Oncology, Vol. 198
-
Development and external validation of the 'Global Surgical-Site Infection' (GloSSI) predictive model in adult patients undergoing gastrointestinal surgery
British Journal of Surgery, Vol. 111, Núm. 6
-
EUSOMA quality indicators for non-metastatic breast cancer: An update
European Journal of Cancer, Vol. 198
-
Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis
Blood, Vol. 144, Núm. 8, pp. 873-887
-
Recent outcomes of liver transplantation for Budd-Chiari syndrome: A study of the European Liver Transplant Registry (ELTR) and affiliated centers
Hepatology, Vol. 80, Núm. 1, pp. 136-151
-
Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients
Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
2023
-
European Society of Breast Cancer Specialists/Advanced Breast Cancer Global Alliance quality indicators for metastatic breast cancer care
European Journal of Cancer, Vol. 187, pp. 105-113
-
Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union’s new recommendations on lung cancer screening
ERJ Open Research
-
Neurobiology of eating behavior, nutrition, and health
Journal of Internal Medicine, Vol. 294, Núm. 5, pp. 582-604
-
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Journal of Clinical Oncology, Vol. 41, Núm. 8, pp. 1590-1599
-
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study
eClinicalMedicine, Vol. 63
-
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19
Genome Medicine, Vol. 15, Núm. 1
-
Results from the european survey on preoperative management and optimization protocols for PeriHilar cholangiocarcinoma
HPB, Vol. 25, Núm. 11, pp. 1302-1322
-
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF -Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
Journal of Clinical Oncology, Vol. 41, Núm. 2, pp. 212-221
-
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial
JAMA Oncology, Vol. 9, Núm. 12, pp. 1688-1695
-
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
ESMO Open, Vol. 8, Núm. 3
2022
-
A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells
Cell Metabolism, Vol. 34, Núm. 6, pp. 857-873.e9
-
Genomic profiling for clinical decision making in lymphoid neoplasms
Blood
-
Identifying FGFR2 fusions/rearrangements in cholangiocarcinoma patients using a novel cfDNA algorithm for treatment with RLY-4008, a highly selective irreversible FGFR2 inhibitor
European Journal of Cancer, Vol. 174, pp. S116